UNSPSC 51422422: Fludrocortisone hemisuccinate

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H33FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MS1UFS6FAB, chemically known as pregn-4-ene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-, 21-(hydrogen succinate), but more generally known as fludrocortisone hemisuccinate, which bears US NIH Compound Identifier 31871. European Medicines Agency schedules fludrocortisone hemisuccinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07684MIG.

Most nations, for tariff purposes, schedule fludrocortisone hemisuccinate under HS 29372200. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)O)O)C)O)F.

UNSPSC 51422422 Fludrocortisone hemisuccinate is a Commodity code nominally identifying a specific pharmaceutical compound, but recent state and local solicitations tagged under this code show little alignment with the pharmaceutical specification itself. The two opportunities posted under this code — one from Seminole County, Florida for naloxone and drug deactivation systems, and one from the Texas Health and Human Services Commission for direct-to-manufacturer prescription program capabilities — do not involve fludrocortisone hemisuccinate procurement or related corticosteroid medications. The mismatch suggests either miscoding in the source procurement systems or that the code is being applied to broader pharmacy and pharmaceutical supply initiatives outside its nominal scope. Issuing bodies using this code include county health departments and state health agencies, but the limited recent activity and categorical mismatch make it difficult to characterize a coherent scope of work or buying pattern.

Geographic activity appears concentrated in Texas and Florida based on the two recent records, with no additional states represented in the current opportunity set. The Seminole County IFB (60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the county community health building; the contract includes a two-year initial term with one-year renewal option and requires drug-free workplace certification and E-Verify compliance. The Texas HHS Commission RFI (HHS0017013), posted April 3, 2026, seeks vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, functioning as preliminary market intelligence to inform future formal procurement strategy rather than a binding solicitation. No award values, budget ranges, or set-aside designations are specified in either opportunity. The code shows minimal recent activity and a weak connection to its stated pharmaceutical commodity, suggesting a watch posture unless your firm actively pursues county-level naloxone supply or state pharmacy benefit program contracting in Florida or Texas.